tradingkey.logo
tradingkey.logo

Caris Life Sciences Inc

CAI
View Detailed Chart
17.290USD
-1.040-5.67%
Market hours ETQuotes delayed by 15 min
4.81BMarket Cap
LossP/E TTM

Caris Life Sciences Inc

17.290
-1.040-5.67%
Intraday
1m
30m
1h
D
W
M
D

Today

-5.67%

5 Days

-8.08%

1 Month

-10.14%

6 Months

-40.77%

Year to Date

-35.92%

1 Year

0.00%

View Detailed Chart

Key Insights

Caris Life Sciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 60 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.80.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Caris Life Sciences Inc's Score

Industry at a Glance

Industry Ranking
60 / 209
Overall Ranking
162 / 4546
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Caris Life Sciences Inc Highlights

StrengthsRisks
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 165.26% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 812.03M.
Undervalued
The company’s latest PE is -5.70, at a low 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 36.76K shares of this stock.

Analyst Rating

Based on 10 analysts
Buy
Current Rating
32.800
Target Price
+70.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Caris Life Sciences Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Caris Life Sciences Inc Info

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Ticker SymbolCAI
CompanyCaris Life Sciences Inc
CEOHalbert (David Dean)
Websitehttps://www.carislifesciences.com/
KeyAI